Skip to main content
Clinical Trials/NCT02121067
NCT02121067
Completed
Phase 4

Intrauterine Contraceptive Insertion at Two-weeks Postpartum: A Study of Acceptability and Short-term Outcomes

University of North Carolina, Chapel Hill1 site in 1 country50 target enrollmentSeptember 2014

Overview

Phase
Phase 4
Intervention
Levonorgestrel Intrauterine System (LNG-IUS)
Conditions
Contraception
Sponsor
University of North Carolina, Chapel Hill
Enrollment
50
Locations
1
Primary Endpoint
Number of Participants Who Would Recommend the LNG-IUS to a Friend at 6-months Postpartum.
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This is a study of 50 postpartum women interested in having the Mirena® LNG-IUS placed for contraception. The Mirena® is an FDA approved intrauterine contraceptive device that provides contraception for 5 years with excellent effectiveness. Women enrolled in this study will only have the Mirena® placed at two-weeks postpartum (day 14-20 postpartum). The participants will be followed at 6-weeks and 6-months postpartum for study visits to evaluate for satisfaction, symptoms, expulsion, and perforation. The study will be completed at six-months postpartum, and participants will be able to keep their LNG-IUS following study completion.

Registry
clinicaltrials.gov
Start Date
September 2014
End Date
June 2016
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Desiring a LNG-IUS
  • Postpartum, ages 18-45 who deliver at a gestational age \> 32 weeks, delivery can be via cesarean or vaginal delivery
  • Following a viable, singleton pregnancy
  • Willing to return to UNC for their LNG-IUS insertion and study follow-up
  • Who plan to stay in the UNC area for 6 months and willing to return to UNC for 3 visits
  • Fluent in English or Spanish
  • At risk of repeat pregnancy (i.e. excluding those who had tubal sterilization)

Exclusion Criteria

  • No genital bleeding of unknown etiology
  • No personal history of known or suspected breast carcinoma
  • No 4th degree vaginal laceration at time of delivery
  • No documented uterine rupture during delivery
  • No active liver disease (resolved pre-eclampsia may enroll)
  • No evidence of vaginal, cervical or uterine infection at time of LNG-IUS insertion
  • No history of postpartum endometritis treated with antibiotics or a postpartum readmission for a dilation and curettage
  • No pre-existing contraindication to a LNG-IUS as determined by the CDC's Medical Eligibility Criteria (MEC) category 3 or 4
  • Not currently incarcerated
  • No known congenital or acquired uterine anomaly, including fibroids that distort the uterine cavity

Arms & Interventions

LNG-IUS placed at 2 weeks postpartum

Enrolled women will have the LNG-IUS placed at two-weeks (14-20 days) postpartum

Intervention: Levonorgestrel Intrauterine System (LNG-IUS)

Outcomes

Primary Outcomes

Number of Participants Who Would Recommend the LNG-IUS to a Friend at 6-months Postpartum.

Time Frame: 6 months postpartum

A dichotomous, yes/no answer to the following question "Would you recommend Mirena placement at two-weeks postpartum to a friend?"

Number of Participants Who Enrolled and Were Able to Have a Successful LNG-IUS Insertion in the 2 Week (Day 14-20) Postpartum Period.

Time Frame: Day 14-20 postpartum

Was the LNG-IUS successfully placed in the study period, as determined by whether the participant had an LNG-IUS placed on the day of insertion?

Secondary Outcomes

  • Number of Participants With Expulsion (Complete or Partial) of LNG-IUS at Six-months.(6 months postpartum)

Study Sites (1)

Loading locations...

Similar Trials